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CELLULAR NEUROSCIENCE
(Bergqvist et al., 2008). The mechanisms underlying this transient 
newborn analgesia at present remain unknown. Here, we explored 
an  involvement  of  oxytocin  in  newborn  analgesia.  Oxytocin, 
who’s levels sharply increase during vaginal delivery, is not only 
involved in labor but also exerts multiple actions in the nervous 
system (Argiolas and Gessa, 1991; Gimpl and Fahrenholz, 2001; 
Raggenbass, 2001; Russell et al., 2003; Tomizawa et al., 2003; Huber 
et al., 2005; Kosfeld et al., 2005; Theodosis et al., 2006). In adult rats, 
oxytocin exerts an analgesic action (Arletti et al., 1993; Lundeberg 
et al., 1993, 1994; Agren et al., 1995; Petersson et al., 2001; Yu et al., 
2003; Condés-Lara et al., 2006; Miranda-Cardenas et al., 2006). The 
analgesic effects of oxytocin in adults is mediated by GABAergic 
inhibition of the nociceptive inputs to the dorsal horn of the spinal 
cord (Condés-Lara et al., 2009). Nociception is strongly regulated 
not only by amount of the GABA(A) receptor mediated anionic 
conductance, but also by its reversal potential (EGABA), as depolar-
izing shifts in EGABA in the nociceptive and dorsal horn neurons 
are associated with elevated pain (De Koninck, 2007; Price et al., 
2009). Pain is alleviated by pharmacological blockade or genetic 
knock out of NKCC1 chloride co-transporter, which is the primary 
cause for elevated chloride and depolarizing action of GABA in 
the nociceptive neurons (Delpire and Mount, 2002; Granados-
Soto et al., 2005; Pieraut et al., 2007; Rocha-González et al., 2008). 
In the immature cortical neurons, oxytocin and NKCC1 blockers 
INTRODUCTION
Delivery is stressful and potentially painful event for the newborn 
(Lagercrantz and Bistoletti, 1977; Bistoletti et al., 1983; Hagnevik 
et  al.,  1984;  Lagercrantz  and  Slotkin,  1986;  Fitzgerald,  2005). 
Sources of pain during delivery can be natural, such as mechani-
cal compression of the fetus (Derek, 1999), and iatrogenic, such 
as forceps extraction, blood samples – including fetal scalp blood 
samples – and injections. Clinical studies indicate that painful 
experiences in neonates may disrupt the adaptation of newborn 
infants to their postnatal environment and in the long term, lead 
to psychological sequelae (Anand and Hickey, 1987). In mice, early 
exposure to noxious or stressful stimuli alters pain sensitivity and 
behavior in adult life, possibly by altering the stress-axis and anti-
nociceptive circuitry (Sternberg et al., 2005; Laprairie and Murphy, 
2009). Therefore, the problem of pain and its treatment in the 
newborn is of clinical importance (Anand, 2001; Slater et al., 2010); 
however, the mechanisms involved in pain regulation at birth are 
poorly understood.
Recently, comparison of the pain responses in human neonates 
born with vaginal delivery or elective cesarean section revealed 
diminished physiological, behavioral and vocalization responses 
to painful stimuli following vaginal delivery when compared to 
C-sections, suggesting that antinociceptive mechanisms are acti-
vated and last for few hours during and after normal delivery 
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et al., 2008). We now report that oxytocin causes pain relief in the 
newborn at birth, via reduction in depolarizing action of GABA 
on the nociceptive neurons.
MATERIALS AND METHODS
ANIMALS
All animal use protocols conformed to the INSERM guidelines 
and the Italian act Decreto Legislativo 27/1/92 n. 116 implement-
ing the European Community directives n. 86/609 and 93/88 on 
the use of laboratory animals. Pregnant and maternal Wistar rats 
were housed with a 12-h light–dark cycle, at 24 ± 1°C, and food and 
water ad libitum. Pregnant rats were monitored hourly on the day 
of expected delivery. During delivery, which lasts in the rat from a 
30 min to 1 h, newborn pups were numbered, weighted and stored 
in a warmed box prior to the pain assays. Delay from delivery to 
the onset of pain assays varied from 30 min to 1 h. Pups born first 
were assayed first. Together with the time for the pain tests and 
drug injections (tests for each drug were performed 30 min after 
injection) all the measurements were obtained within 2 h after birth.
QUANTIfICATION Of THE NOCICEpTIvE RESpONSE
Tail immersion
The pup was held in a box with a hole allowing the tail to pro-
trude from it. The inner surface of the box was covered with an 
aluminum sheet forming an electrical contact with the rat body. 
The electrical circuit via the sheet, body, tail, and water bath was 
powered by a 1.5-V battery and its connection and disconnection 
could be easily detected upon the tail immersion and withdrawal 
from the water, respectively. Electrical signals were digitized at 
1 kHz using a Digidata 1200 and recorded to a computer. The dis-
tal tip of the tail was lowered into the water bath (50°C). Latency 
to withdrawal was recorded as the “pain” parameter, with a 15-s 
maximum allowable threshold. After three habituation tests, the 
latency to withdrawal was determined from the average of three 
consecutive measurements.
Vocalization
Under isoflurane (1.5%) anesthesia, rat pups were implanted with 
bipolar electrodes into the whisker pad and decerebrated at the 
upper pons level. After 10 min (P0) or 1 h (P1–2 pups) of recovery, 
the pups were wrapped by cotton and placed on a thermal blanket 
(38°C). The whisker pad was stimulated by electrical pulse trains 
(1 ms pulse duration, 5–25 V amplitude, 50 Hz, 1 min inter-train 
interval). It has been shown that pain vocalization includes A-delta 
and C-fibers – triggered audible “peeps” (with the most prominent 
peak at 4–5 kHz) and “chatters” (peak at 2.5 kHz) followed by 
ultrasonic vocalizations patterned by respiration cycles (Jourdan 
et al., 1995, 1997). In the present study, audible component of the 
vocalization response was recorded by microphone, digitized at 
10 kHz using Digidata 1440 interface (Axon Instruments) and 
analyzed offline using Matlab (MathWorks, Natick, MA, USA). To 
quantify the vocalization response, we calculated scalar integral 
(Σ) as following: (i) raw sonogram was converted to scalar sono-
gram by inverting all negative values to positive values; (ii) scalar 
sonogram was corrected for the baseline activity level by subtrac-
tion of the mean scalar sonogram value calculated during 1 min 
before stimulation; (iii) scalar sonogram integral was calculated 
as cumulative, corrected for the baseline, scalar sonogram during 
5 s after stimulation.
Calcium imaging
Trigeminal sensory neurons were obtained from P0 rats. Animals 
were anesthetized and decapitated. Trigeminal ganglia were excised 
and enzymatically dissociated in F12 medium containing 0.25 mg/
ml trypsin, 1 mg/ml collagenase, and 0.2 mg/ml DNase (Sigma) 
at 37°C. Cells were plated on poly-l-lysine-coated Petri dishes in 
F12 medium with 10% fetal bovine serum and examined 5 h after 
plating. For Ca2+ imaging experiments cells were incubated for 
40 min at 20–22°C in physiological solution containing fluo-3 
(AM  ester  cell-permeable  compound;  1  µM;  Invitrogen),  fol-
lowed by a 30-min washout period. Fluorescence in neurons was 
imaged using Cell-R imaging system (Olympus Europe, Hamburg, 
Germany). The imaging system consisted of the Olympus IX-70 
inverted microscope equipped with a 175-W xenon burner light 
source. Fluorescence of fluo-3 was excited at 490 ± 5 nm and 
collected at 520 ± 15 nm. Images were collected in a time-lapse 
mode (2 Hz; 100 ms exposure time) with a CCD camera (Orca, 
Hamamatsu,  Japan).  To  prevent  photobleaching,  illumination 
was used only during agonist application (with 10 min intervals). 
Fluorescent signals from single cells were quantified as the ∆F/F0, 
where F0 is the background subtracted baseline fluorescence and 
DF is the increment over the baseline). All drugs were applied via 
fast perfusion system (solution exchange time ∼30 ms, RDS-200, 
Bio-Logic - Science Instruments, Grenoble, France). P2X3 recep-
tors were activated with the selective agonist a,b-methylenATP 
(a,b-meATP, 10 µM) while TRPV1 receptors were activated with 
capsaicin (200 nM). Plots and figures were constructed using 
Origin software (OriginLab, version 8.0).
Single GABA channel recordings
Single GABA channel recordings were performed from the trigemi-
nal sensory neurons prepared as described above. Cell-attached 
patch-clamp recordings were performed using EPC-9 amplifier 
(HEKA Elektronik Dr. Schulze GmbH, Lambrecht/Pfalz, Germany). 
Patch  electrodes  were  made  from  borosilicate  glass  capillaries 
(GC150F-15, Clark Electromedical Instruments). For recordings 
of single GABA(A) channels, patch pipette solution contained (in 
mM): NaCl 120, TEA-Cl 20, KCl 5, 4-aminopyridine 5, CaCl2 0.1, 
MgCl2 10, glucose 10, HEPES–NaOH 10 buffered to pH 7.2–7.3 
and GABA (1–5 µM) was added at the day of experiment from 
1 mM frozen stock solution. Driving force for GABA(A) receptor 
mediated currents was determined from the current–voltage rela-
tionships of the currents through single GABA(A) channels single 
as described earlier (Tyzio et al., 2006) and corrected for an error 
of 2 mV (Tyzio et al., 2008).
Drugs
In the experiments in vivo, oxytocin (Sigma-Aldrich, St. Louis, MO, 
USA) 50 µM was injected at 0.1 ml/5g (diluted in saline) i.p., 30 min 
before testing. Bumetanide (Burinex, LEO pharmaceutical Products, 
Denmark) solution 25 µg/ml was injected i.p. at the dose of 5 µmol/
kg, 30 min before testing. Atosiban (Sigma) (diluted in saline) was 
injected at 2 µg/kg, i.p., 30 min before   testing. SSR126768A (gift 
Frontiers in Cellular Neuroscience  www.frontiersin.org  April 2011  | Volume 5  | Article 3  |  2
Mazzuca et al.  Oxytocin, newborn and painand only increase to adult values by the second or third postnatal 
week (Fitzgerald and Gibson, 1984; Falcon et al., 1996; Jiang and 
Gebhart, 1998; Teng and Abbott, 1998; Marsh et al., 1999). We 
studied thermal tail-flick responses in two age groups: (i) newborn 
animals within an hour after birth (P0) and (ii) 2-day-old rat pups 
(P2). Oxytocin levels are maximal during and immediately after 
birth, and wane during the first postnatal day, as deduced from 
the dynamic changes in GABA signaling in the cortical neurons 
(Tyzio et al., 2006). Under control conditions, P0 rats withdrew 
their tails within 4.7 ± 0.19 s (n = 15; Figure 1A). In P2 rats, delay 
in the tail withdrawal was of 2.4 ± 0.16 s (n = 15; Figure 1B), 
that is nearly two times shorter than P0 control rats (P < 0.0001). 
Thus, pain sensitivity in the newborn rats is significantly lower than 
in 2-day-old rats. To determine the contribution of endogenous 
oxytocin to this difference, we used selective blockers of oxytocin 
receptors atosiban (2 µg/kg, i.p.) and SSR126768A (1 µg/kg, i.p.). 
Both competitive antagonists caused a nearly three-fold accelera-
tion of tail withdrawal in P0 pups; rendering them similar to that 
seen in P2 rats under control conditions (Figures 1A,B). In con-
trast, oxytocin receptor blockers did not significantly modify the 
tail-flick delays in P2 animals (Figure 1B). These findings suggest 
a strong analgesic effect of endogenous oxytocin in the newborn 
rats, and that this effect wanes with a postnatal reduction in oxy-
tocin levels. Systemic administration of exogenous oxytocin (1 µg/
kg) resulted in a dramatic analgesic effect both in newborn and 
P2 rats (Figures 1A,B). In the newborn rats, exogenous oxytocin 
could also partially reverse the effects of the competitive oxytocin 
from Sanofi-Synthelabo) diluted in saline injected at 1 µg/kg i.p, 
30 min before testing. Sham injections in the control group were 
performed with equal volumes of saline.
Statistical analysis
Results are expressed as mean ± SEM. Data were analyzed by a 
two-way analysis of variance (ANOVA) followed, when the F value 
was significant, by a Fischer t-test, when the time-course of the 
effect was compared. Significance of changes in experiments with 
vocalization in vivo was tested by the Kruskal–Wallis test (H-test). 
In calcium imaging experiments significance was analyzed by non-
parametric Mann–Whitney test. The level of statistical significance 
(*) was set at P < 0.05.
RESULTS
In the present study, we used a combination of behavioral tests 
including thermal tail-flick and electrical stimulation evoked vocal-
izations, as well as electrophysiological and imaging approaches in 
isolated trigeminal neurons to study pain control by oxytocin in 
the newborn rats.
ANALgESIC ACTIONS Of OxyTOCIN wITH THERMAL TAIL-fLICk ASSAy
We first tested pain sensitivity in the newborn rats using a thermal 
tail-flick response. In this test, pain sensitivity is reciprocal to the 
delay in tail withdrawal from the hot water. Previous developmen-
tal studies using this test indicated that nociceptive withdrawal 
thresholds are low in rat pups during the first postnatal week 
FiGure 1 | Oxytocin induces analgesia in newborn rat pups. Tail-flick pain 
response in the newborn (A) and 2-day-old (B) rat pups. Inset: schematic 
drawing of the tail-flick pain test, in which the pup’s tail is immersed in hot water 
(50°C) and the delay of tail withdrawal (∆T) is used as a measure of pain. Note 
that in the newborn (P0) rats, oxytocin receptor blockers atosiban and 
SSR126768A strongly accelerate tail withdrawal, whereas oxytocin and the 
NKCC1 antagonist bumetanide alleviate pain. In 2-day-old rat pups, in which 
endogenous oxytocin levels waned, pain responses are much stronger than in 
the newborn rats and blockade of oxytocin receptors does not modify the 
response, however, exogenous oxytocin and bumetanide still exert powerful 
analgesic action (mean ± SEM; 5–15 animals for each column; ***P < 0.001; 
n.s., P > 0.05).
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not   saturated, and that   therapeutic elevation of oxytocin levels 
could result in more powerful analgesia in the newborn.
ANALgESIC ACTIONS Of OxyTOCIN wITH pAIN-INDUCED 
vOCALIzATION
As a second approach, we studied oxytocin-dependent modulation 
of trigeminal pain responses by measuring vocalization induced 
by electrical stimulation of the whisker pad. Animals were decer-
ebrated at caudal midbrain levels (Figure 2A) to cut the descend-
ing oxytocin projections from the VPN and to prevent noxious 
input to the forebrain. Electrical stimulation of the whisker pad 
evoked vocalization in the neonatal rats despite this decerebra-
tion (Figure 2). Vocalizing responses were composed of several 
bursts with a dominant frequency in the range from 2.7 to 5 kHz 
(mean frequency 3.9 ± 0.1 kHz, n = 24, rat P0–2). To quantify 
vocalization response, we calculated a scalar sonogram integral. 
In agreement with the results of the thermal tail-flick assay, the 
oxytocin receptor blocker atosiban (2 µg/kg) increased vocaliza-
tion responses in P0 rats (to 155 ± 28% of control values, n = 8, 
P = 0.0003; Figure 3A). In P1–2 rats, injections of saline did not 
change the vocalization response (105 ± 21% of control values; 
n = 6; P > 0.05). However, exogenous oxytocin strongly reduced 
vocal responses from 15.2 ± 6.4 to 8.2 ± 5.6 a.u., that is to 42 ± 12% 
(n = 6; P = 0.00004), and this effect was partially reversed by 
FiGure 2 | Oxytocin reduces electrical stimulation evoked vocalizations in 
decerebrated newborn rat pups. (A) Experimental setup. A train of electrical 
stimuli (E.S.) is delivered to the whisker pad, and the vocalizations are recorded by 
microphone. Right, photograph of the sagittal brain section showing the 
decerebration cut. (B) Time course of the effect of oxytocin on vocalizations 
(a.u = arbitrary unit). (C) Sonogram of the electrostimulation evoked vocalization in 
P1 pup in control conditions (left trace) and 20 min after administration of oxytocin 
(1 µmol/kg, i.p.; right trace). Spectrograms of the vocalization responses are 
shown under each trace. Insets show corresponding scalar vocalization response 
(gray bars, left ordinate) and scalar vocalization integral (red line, right ordinate).
FiGure 3 | Summary plot of the oxytocin modulation of vocalization 
responses. Scalar vocalization integrals of the responses evoked by electrical 
whisker pad stimulation in decerebrated rat pups at P0 (A) and at P1–2 (B). 
Vocalization integrals are normalized to the control values. Note that 
vocalizations are enhanced by the oxytocin receptor antagonist atosiban in the 
newborn rats, and that they are reduced by exogenous oxytocin and NKCC1 
blocker bumetanide in P1–2 rat pups. *P < 0.05; **P < 0.01; ***P < 0.001; 
n.s., P > 0.05.
atosiban to 84 ± 38% from the control values (n = 6; P = 0.0017, 
Figures 2 and 3). Taken together, the results of both behavioral tests 
indicate that endogenous oxytocin reduces pain in newborn rats.
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et al.,1994; Wang et al., 1994), activation of GABA receptors induced 
robust transient increases of intracellular calcium in trigeminal 
neurons, indicating a depolarizing action of GABA and calcium 
entry into the cells via voltage-gated calcium channels (Figure 4). 
Application of 1 µM oxytocin induced slow transient responses last-
ing ∼60–80 s (not shown) and significantly reduced GABA-evoked 
calcium transients. It is known that the depolarizing action of 
GABA in sensory neurons results from elevated intracellular chlo-
ride concentration, set by the highly expressed NKCC1 membrane 
chloride co-transporter (Delpire and Mount, 2002). In keeping with 
this observation, bumetanide suppressed GABA-evoked calcium 
transients like oxytocin confirming the importance of chloride and 
GABA in mediating these analgesic responses (Figures 4A,B).
To determine the specificity of oxytocin/GABA interactions in 
pain modulation, we tested the effects of the hormone on P2X3 
receptors and TRPV1 receptors which represent two major types 
of pain transducers in trigeminal neurons (Simonetti et al., 2006). 
Figure 5 shows that repetitive (at 10 min intervals) 2 s long applica-
tions of the selective P2X3 receptor agonist a,b-meATP (n = 276 
cells) and the TRPV1 agonist capsaicin (n = 223 cells) evoked 
transient, and essentially reproducible Ca2+ transients in neonatal 
trigeminal neurons. Application of 1 µM oxytocin for 20–30 min 
did not change the amplitude of these responses (n = 283 and 248 
cells for a, b-meATP and capsaicin, respectively). Thus, oxytocin 
does not modify P2X3 and TRPV1 receptor mediated responses in 
trigeminal neurons, further supporting our hypothesis that antino-
ciceptive effects of oxytocin involve modulation of GABA signaling 
in the nociceptive neurons.
ANALgESIC ACTIONS Of OxyTOCIN ARE MEDIATED by gAbA 
SIgNALINg
Oxytocin induces a transient excitatory-to-inhibitory switch in the 
action of GABA on immature neurons at birth (Tyzio et al., 2006), 
and GABAergic mechanisms are implicated in the analgesic actions 
of oxytocin in adult animals (Condés-Lara et al., 2009). To examine 
the role of oxytocin-mediated regulation of GABA current polarity 
in neonatal analgesia, we used bumetanide – a selective blocker 
of NKCC1 co-transporter that, like oxytocin, lowers intracellular 
chloride and shifts the depolarizing/excitatory actions of GABA 
on immature neurons (Tyzio et al., 2006). Bumetanide (5 µmol/
kg) strongly delayed the tail-flick responses in both age groups, 
and, importantly, prevented effects of oxytocin receptor blockers 
in newborn rats (Figure 1). Vocalizations induced in decerebrated 
pups were also reduced in P1–2 rats by bumetanide to 72 ± 16% of 
control (n = 6; P = 0.004, Figure 3). Taken together, these results 
suggest that endogenous oxytocin reduces pain in newborn rats by 
shifting the level of intracellular chloride that in turn changes the 
action of GABA in the pain circuits.
OxyTOCIN MODULATES gAbA SIgNALINg IN THE pRIMARy 
NOCICEpTIvE NEURONS
As the actions of oxytocin in adult rats involve modulation of 
GABAergic control of the primary nociceptive afferents (Condés-
Lara et al., 2009), we studied the effect of oxytocin on GABA 
responses in trigeminal sensory neurons, which detect noxious 
stimuli from the head and facial tissues and conduct them to the 
brainstem. Experiments were performed in primary cultures of 
trigeminal neurons dissociated from newborn rats and kept for 
FiGure 4 | Oxytocin and bumetanide similarly reduce the depolarizing 
action of GABA on neonatal rat primary nociceptive neurons in vitro. 
(A) Examples of Ca2+ transients in isolated neonatal (P0) trigeminal sensory 
neurons induced by two sequential applications of GABA (100 µM at 30 min 
interval) in control conditions (top traces), and after 30 min exposure to 1 µM 
oxytocin (middle traces) and 10 µM bumetanide (bottom traces). 
(B) Summary plot shows the time course of changes in the normalized 
amplitude of GABA-induced Ca2+ transients in control conditions (n = 56 
cells), and during application of oxytocin (n = 31 cells) and bumetanide 
(n = 15 cells).
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this short period because developmental studies indicate that pain 
sensitivity only reduces with age (Fitzgerald and Gibson, 1984; 
Falcon et al., 1996; Jiang and Gebhart, 1998; Teng and Abbott, 1998; 
Marsh et al., 1999), but rather reflects a birth-related phenomenon. 
Secondly, blockade of oxytocin receptors that did not significantly 
modify the response in P2 rats, when birth-derived oxytocin levels 
have waned, but did strongly increase pain sensitivity in the rats 
immediately after birth. The present results are in agreement with 
clinical findings of newborn analgesia in vaginal delivery when 
compared to elective cesarean sections without labor (Bergqvist 
et al., 2008). Relying on this observation, it has been proposed that 
the fetus exhibits a high pain threshold during delivery, and that this 
threshold decreases significantly within hours after spontaneous 
vaginal birth. Thus, newborn analgesia exists both in human and 
rodent suggesting that it is a fundamental mechanism developed 
and conserved through the mammalian evolution. The physiologi-
cal role for the newborn analgesia is likely to prevent newborns from 
experiencing the pain inherent in the mechanical compression in 
Because the results of calcium imaging suggest that oxytocin 
reduces the depolarizing action of GABA, we studied the effect of 
oxytocin on the GABA driving force (DFGABA) using cell-attached 
recordings of single GABA(A) channels (Figure 6). DFGABA was 
deduced from reversal potential of the currents via GABA(A) chan-
nels (Serafini et al., 1995; Tyzio et al., 2006, 2008). In control condi-
tions, GABA exerted strongly depolarizing action on the immature 
trigeminal neurons with DFGABA of 38.7 ± 2.4 mV (n = 6). In the 
presence of oxytocin (1 µM), DFGABA was reduced to 17.7 ± 6.7 mV 
(n = 5; P < 0.05), indicating that oxytocin strongly diminishes the 
depolarizing action of GABA on neonatal trigeminal neurons via a 
reduction of intracellular chloride as described in neonatal cortical 
neurons (Tyzio et al., 2006).
DISCUSSION
Our results indicate that like human neonates (Bergqvist et al., 
2008), newborn rats are born with a natural analgesia. Firstly, pain 
sensitivity in the thermal tail-flick assay was significantly lower in 
the newborn rats compared to P2 rats. This difference is unlikely 
FiGure 5 | Oxytocin does not affect P2X and TrPV1 receptor mediated 
calcium transients in the neonatal rat primary nociceptive neurons in vitro. 
Dynamics of mean amplitudes of a,b-meATP (A) and capsaicin (B)-evoked 
calcium responses under control conditions (open circles; n = 276 and 223 cells 
for a,b-meATP and capsaicin, respectively) and during oxytocin application 
(triangles; n = 283 and 248 cells, respectively).
FiGure 6 | Oxytocin reduces depolarizing action of GABA measured 
using cell-attached recordings of single GABA channels from the 
neonatal rat primary nociceptive neurons in vitro. (A) Current–voltage 
relationships of the currents through single GABA channels recorded from 
isolated trigeminal neurons in vitro under control conditions and in the 
presence of oxytocin (1 µM). Examples of recordings at different pipette 
potentials (Vp) are shown on inset. (B) Summary plot shows the values of 
DFGABA in control conditions and in the presence of oxytocin. Each circle 
corresponds to individual neuron. Note that oxytocin reduces DFGABA in 
trigeminal neurons.
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newborns (Bergqvist et al., 2008), elevated oxytocin levels under 
normal delivery but not during C-sections (Russell et al., 2003; Wei 
et al., 2009), and by the analgesic effects of oxytocin in humans 
(Yang, 1976). On the other hand, the level of maturity of human 
brain at term is more advanced compared with altricial rats (Clancy 
et al., 2001) and nociceptive systems undergo significant changes 
during development (Fitzgerald and Gibson, 1984; Falcon et al., 
1996; Jiang and Gebhart, 1998; Teng and Abbott, 1998; Marsh et al., 
1999). In regards to the source of oxytocin, the contribution of 
fetal oxytocin to perinatal analgesia may be more significant in 
humans as their hypothalamo-neurohypophyseal system is more 
advanced at term and is capable of producing proper oxytocin. 
Thus, in humans, oxytocin levels at birth are higher in the umbili-
cal artery than in the umbilical vein (Chard et al., 1971; Dawood 
et al., 1978; Otsuki et al., 1983; Patient et al., 1999). In addition, 
no oxytocin was detected in either arterial or venous cord blood 
of anencephalic newborns (Chard et al., 1971; Otsuki et al., 1983). 
This may suggest that oxytocin-mediated newborn analgesia in the 
rat is mainly provided by mother oxytocin whereas in human, it is 
mainly provided by fetal oxytocin.
How does oxytocin exert an analgesic action? In adult rats, elec-
trical stimulation of the PVN, or topical application of oxytocin, 
selectively inhibits A-delta and C-fiber responses in superficial 
dorsal horn neurons, and this inhibition is reversed by a selective 
oxytocin antagonists (Robinson et al., 2002; Condés-Lara et al., 
2006; Rojas-Piloni et al., 2007, 2008). These effects are blocked by 
the GABA(A) receptor antagonist bicuculline, suggesting that the 
analgesic actions of oxytocin involve enhancement of presynaptic 
GABAergic inhibition of the primary nociceptive inputs conveyed 
by A-delta and C-fibers to the spinal cord (Condés-Lara et al., 2009). 
This is in keeping with a preferential expression of oxytocin recep-
tors in the superficial layers of the dorsal spinal cord, which is 
already high at birth (Uhl-Bronner et al., 2005).
An increase in GABAergic inhibition of the primary nocicep-
tive afferents likely contributes to the analgesic actions of oxytocin 
observed in the present study in the newborn rats. However, in 
addition to the increase in the amount of GABA release caused by 
increased interneuron firing, a change in EGABA seems to contrib-
ute to the oxytocin-mediated increase in GABAergic inhibition. 
Indeed, we found that oxytocin reduces DFGABA and reduces GABA-
evoked calcium transients in the trigeminal neurons. EGABA shifts 
toward more depolarizing values in different models of chronic 
pain in adult animals (for reviews De Koninck, 2007; Price et al., 
2009). Blockade of NKCC1 co-transporter, which is the primary 
mediator of chloride accumulation in primary nociceptive neurons 
with bumetanide, causes a negative shift in EGABA and reduces pain 
(Alvarez-Leefmans et al., 1988; Sung et al., 2000; Laird et al., 2004; 
Granados-Soto et al., 2005; Valencia-de Ita et al., 2006). Our find-
ings that bumetanide exerts an analgesic action in rat pups, and 
most notably, that its analgesic action persists after blockade of 
oxytocin receptors, provides additional support to our hypothesis 
that changes in EGABA in the nociceptive neurons are involved in 
the newborn analgesia and analgesic actions of oxytocin. Because 
depolarizing action of GABA on primary nociceptive neurons per-
sists through the development (Alvarez-Leefmans et al., 1988; Sung 
et al., 2000; Gilbert et al., 2007; Rocha-González et al., 2008), it 
the delivery channel. Indeed, during delivery the human newborn’s 
head is squeezed with an intermittent pressure as high as 2 kg/cm−2 
for several hours (Derek, 1999). However, it should equally allevi-
ate pain resulting from iatrogenic factors, including forceps and 
vacuum extraction, placement of electrodes, blood samples during 
labor, and injections of vitamins and immunization. In keeping 
with the time course of newborn analgesia, which wanes within 
few hours, it has been recommended that painful procedures such 
as vitamin K injection or blood sampling to be performed within 
90 min after birth in order to minimize neonatal pain and possible 
long-lasting changes in pain behavior (Bergqvist et al., 2008).
What are the mechanisms of newborn analgesia? Because deliv-
ery is associated with stress, and because stress induces analgesia, 
it likely stress-induced noradrenalin and opioids releases mediate 
newborn analgesia (Bistoletti et al., 1983; Hagnevik et al., 1984; 
Lagercrantz and Slotkin, 1986; Lagercrantz, 1996; Mogil et al., 
1996). The results of the present study also indicate an involvement 
of oxytocin, who’s analgesic actions have been well documented 
in adult animals (Arletti et al., 1993; Lundeberg et al., 1993, 1994; 
Agren et al., 1995; Petersson et al., 2001; Yu et al., 2003; Condés-
Lara et al., 2006; Miranda-Cardenas et al., 2006). Indeed, blockade 
of oxytocin receptors significantly increased pain in both assays in 
the newborn animals, suggesting an involvement of endogenous 
oxytocin. Conversely, exogenous oxytocin exerted analgesic actions 
in the animals newborn and in 1- to 2-day-old rat pups, when 
endogenous oxytocin has waned. Thus, newborn analgesia is likely 
achieved by activation of several complementary antinociceptive 
stress-induced  (catecholamines  and  opioids)  and  birth-related 
(oxytocin) mechanisms to optimally protect newborn from the 
pain. Although the relative contributions of these various mecha-
nisms to newborn analgesia remain to be determined, the powerful 
proalgesic effects of the oxytocin receptor antagonists in the new-
born rats indicate that endogenous oxytocin provides a significant 
contribution to newborn analgesia.
What is the source for oxytocin in the newborn? In the fetal 
brain, oxytocin may be provided both by the mother and the 
fetus, and the maternal and fetal contributions may differ in 
rodents and humans. In the newborn rat the principal source of 
oxytocin is maternal, with only a limited contribution of fetus. 
This  is  because  the  hypothalamo-neurohypophysial  system 
develops mainly post partum (Choy and Watkins, 1979; Lipari 
et al., 2001) and the production of fully functional amidated 
oxytocin begins only after birth and increases rapidly during 
postnatal development (Alstein et al., 1988; Lipari et al., 2001). 
Thus, the onset of intrinsic oxytocin production does not match 
with the observed perinatal oxytocin-mediated changes in GABA 
signaling, which is already half-maximal by E20 (Tyzio et al., 
2006), nor with the analgesic actions of endogenous oxytocin 
at birth. In addition, we found that blockade of oxytocin recep-
tors exerted pro-nociceptive action in the decerebrated newborn 
rats in which the descending oxytocin fibers from PVN and the 
upstream pain pathways are cut. Taken together, these results 
indicate that oxytocin in the newborn rat brain is mainly pro-
vided by the mother.
Whether our findings on the perinatal analgesic action of oxy-
tocin can be translated to human newborn remains unknown. 
However such a hypothesis is supported by the findings of higher 
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